Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
- NCT ID
| Study title | Condition | Phase | Location | NCT ID |
|---|---|---|---|---|
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma |
Asthma | Phase2 | Bulgaria Colombia Guatemala Hungary Poland South Africa Spain United Kingdom View all |
NCT05222529 |
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) |
Progressive Metastatic Castrate Resistant Prostate Cancer | Phase1, Phase2 | Australia Canada China Denmark France Italy Malaysia Poland Singapore Spain United Kingdom United States View all |
NCT07206056 |
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials |
Spinal Muscular Atrophy (SMA) | Phase3 | Australia Belgium Brazil Canada China Denmark France Italy Japan Malaysia Netherlands Saudi Arabia Singapore Spain Taiwan Thailand United Kingdom United States Vietnam View all |
NCT05335876 |
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. |
Relapsing Multiple Sclerosis | Phase3 | Argentina Australia Belgium Canada Denmark France Greece Italy Mexico Portugal Slovakia South Africa Spain Switzerland United Kingdom United States View all |
NCT06846281 |
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET |
Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) | Phase3 | Canada China France Germany Hungary Italy Netherlands Poland South Korea Spain United Kingdom United States View all |
NCT06784752 |
An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis |
Rheumatoid Arthritis | Phase1 | Argentina Bulgaria China France Germany Hungary Netherlands Romania Spain View all |
NCT07029555 |
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS) |
PIK3CA-related Overgrowth Spectrum (PROS) | Phase2 | Australia Austria Belgium France Germany Italy Spain Switzerland United States View all |
NCT06997588 |
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension) |
Lupus Nephritis | Phase3 | Brazil China Colombia Hungary Mexico Romania Singapore South Korea Taiwan Thailand View all |
NCT06711887 |
Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study |
Relapsing Multiple Sclerosis (RMS) | Greece | NCT06486779 | |
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia |
Familial Hypercholesterolemia - Homozygous | Phase3 | Austria China Germany Greece Malaysia Netherlands South Africa Taiwan Turkey (Türkiye) United Kingdom United States View all |
NCT06597006 |